Citigroup’s Novo Nordisk NVO Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $9.25M | Sell |
193,000
-25,000
| -11% | -$1.07M | ﹤0.01% | 1680 |
|
|
2026
Q1 | $8.01M | Buy |
218,000
+85,000
| +64% | +$4.03M | ﹤0.01% | 1608 |
|
|
2025
Q4 | $6.77M | Buy |
133,000
+10,000
| +8% | +$511K | ﹤0.01% | 1804 |
|
|
2025
Q3 | $6.83M | Buy |
123,000
+93,000
| +310% | +$5.44M | ﹤0.01% | 1767 |
|
|
2025
Q2 | $2.07M | Hold |
30,000
| – | – | ﹤0.01% | 2619 |
|
|
2025
Q1 | $2.08M | Sell |
30,000
-228,800
| -88% | -$18.9M | ﹤0.01% | 2668 |
|
|
2024
Q4 | $22.3M | Buy |
258,800
+231,300
| +841% | +$25M | 0.01% | 898 |
|
|
2024
Q3 | $3.27M | Buy |
+27,500
| New | +$3.67M | ﹤0.01% | 2216 |
|
|
2021
Q1 | – | Sell |
-92,800
| Closed | -$3.24M | – | 7043 |
|
|
2020
Q4 | $3.24M | Buy |
92,800
+26,400
| +40% | +$913K | ﹤0.01% | 2411 |
|
|
2020
Q3 | $2.31M | Buy |
66,400
+2,600
| +4% | +$86.7K | ﹤0.01% | 2527 |
|
|
2020
Q2 | $2.09M | Sell |
63,800
-8,800
| -12% | -$281K | ﹤0.01% | 2764 |
|
|
2020
Q1 | $2.19M | Sell |
72,600
-4,800
| -6% | -$143K | ﹤0.01% | 2391 |
|
|
2019
Q4 | $2.24M | Sell |
77,400
-62,600
| -45% | -$1.73M | ﹤0.01% | 2848 |
|
|
2019
Q3 | $3.62M | Buy |
140,000
+64,400
| +85% | +$1.63M | ﹤0.01% | 2232 |
|
|
2019
Q2 | $1.93M | Buy |
75,600
+20,200
| +36% | +$499K | ﹤0.01% | 2896 |
|
|
2019
Q1 | $1.45M | Sell |
55,400
-31,200
| -36% | -$767K | ﹤0.01% | 3000 |
|
|
2018
Q4 | $2M | Buy |
86,600
+24,400
| +39% | +$542K | ﹤0.01% | 2666 |
|
|
2018
Q3 | $1.47M | Sell |
62,200
-20,000
| -24% | -$488K | ﹤0.01% | 3067 |
|
|
2018
Q2 | $1.9M | Buy |
82,200
+54,800
| +200% | +$1.3M | ﹤0.01% | 2719 |
|
|
2018
Q1 | $674K | Sell |
27,400
-27,000
| -50% | -$709K | ﹤0.01% | 3677 |
|
|
2017
Q4 | $1.46M | Sell |
54,400
-5,400
| -9% | -$137K | ﹤0.01% | 2958 |
|
|
2017
Q3 | $1.44M | Buy |
59,800
+26,200
| +78% | +$592K | ﹤0.01% | 2996 |
|
|
2017
Q2 | $721K | Sell |
33,600
-28,800
| -46% | -$581K | ﹤0.01% | 3644 |
|
|
2017
Q1 | $1.07M | Sell |
62,400
-39,800
| -39% | -$693K | ﹤0.01% | 3145 |
|
|
2016
Q4 | $1.83M | Buy |
102,200
+8,800
| +9% | +$160K | ﹤0.01% | 3057 |
|
|
2016
Q3 | $1.94M | Buy |
93,400
+67,800
| +265% | +$1.68M | ﹤0.01% | 2542 |
|
|
2016
Q2 | $688K | Buy |
25,600
+18,600
| +266% | +$510K | ﹤0.01% | 3310 |
|
|
2016
Q1 | $190K | Sell |
7,000
-8,000
| -53% | -$214K | ﹤0.01% | 5137 |
|
|
2015
Q4 | $436K | Buy |
15,000
+11,200
| +295% | +$310K | ﹤0.01% | 3996 |
|
|
2015
Q3 | $103K | Buy |
3,800
+3,600
| +1,800% | +$102K | ﹤0.01% | 4963 |
|
|
2015
Q2 | $5K | Buy |
+200
| New | +$5.62K | ﹤0.01% | 6764 |
|
Other funds holding NVO
F
Citigroup's NVO Position: Q2 2026 in Review
Citigroup reduced its Novo Nordisk (NVO) stake by 35% in Q2 2026, selling an estimated $23.3M and leaving 1,006,032 shares worth $48.2M. The position accounts for 0.02% of the portfolio, ranked #752.
Citigroup first reported a position in NVO in Q2 2013 and has held it in 53 quarters since. The position peaked at $190M in Q2 2024. 1,353 funds tracked by Wall St. Rank hold NVO as of Q2 2026.
- Citigroup held 1,006,032 shares of Novo Nordisk worth $48.2M as of Q2 2026.
- Citigroup sold 541,623 Novo Nordisk shares in Q2 2026, an estimated $23.3M.
- Novo Nordisk made up 0.02% of Citigroup's portfolio in Q2 2026, its #752 holding.
- Citigroup first reported a position in Novo Nordisk in Q2 2013 and has held it in 53 quarters since.
- Citigroup's Novo Nordisk position peaked at $190M in Q2 2024.
- 1,353 funds tracked by Wall St. Rank held Novo Nordisk as of Q2 2026.
Based on Citigroup's 13F filing for Q2 2026, filed 3 Aug 2026.